MEI Pharma, Inc. (MEIP)
| Market Cap | 64.58M |
| Revenue (ttm) | 44.14M |
| Net Income (ttm) | -54.68M |
| Shares Out | 132.99M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,885,695 |
| Open | 0.466 |
| Previous Close | 0.466 |
| Day's Range | 0.449 - 0.489 |
| 52-Week Range | 0.450 - 3.550 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 5.41 (+1,014.1%) |
| Earnings Date | May 26, 2022 |
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and ...
Financial Performance
In 2021, MEI Pharma's revenue was $25.54 million, a decrease of -11.68% compared to the previous year's $28.91 million. Losses were -$50.58 million, 9.91% more than in 2020.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for MEIP stock is "Buy." The 12-month stock price forecast is 5.41, which is an increase of 1,014.09% from the latest price.
News
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to ...
Los Angeles, California--(Newsfile Corp. - May 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MEI Pha...
MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages...
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. (“MEI” or the “Company”)...
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact...
Los Angeles, California--(Newsfile Corp. - May 18, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MEI Pha...
MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Enc...
NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against MEI Pharma, Inc. (“MEI” or the “Company”)...
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MEI Pharma, Inc. (MEIP) ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of MEI Pharma, Inc. (“...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) investors concerning the Company's ...
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Conta...
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright G...
The Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of MEI Pharma, Inc. (“MEI Pharma” or the “Company”) (NASDAQ: MEIP) on behalf of investors concerning the Company...
Rosen Law Firm Encourages MEI Pharma, Inc. Investors with Losses to Inquire About Class Action Investigation – MEIP
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MEI Pharma, Inc. (NASDAQ: MEIP) ...
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Associati...
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151)...
10 Top Penny Stocks To Buy For Under $1 May 2022 Edition
Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for ...
MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two posters presenting preclinical da...
5 Penny Stocks To Buy According To Big Money Options Bets Right Now
Penny stocks with interesting options activity today. The post 5 Penny Stocks To Buy According To Big Money Options Bets Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | Pe...
Mei Pharma (MEIP) to Delay Filing With FDA for Lymphoma Drug
Mei Pharma's (MEIP) FDA filing plans for zandelisib for lymphoma indication get derailed after the agency requests more clinical studies. The stock plummets in after-market trading post this news.
Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update
The FDA crushed MEI Pharma Inc's (NASDAQ: MEIP) hopes of winning accelerated approval for its PI3K inhibitor, zandelisib, on the strength of phase 2 data. In the meeting, the FDA informed that a randomi...
Penny Stocks Today: Why MEIP and HNST Are Plunging Friday
We're checking in on the latest penny stocks news for today with two companies that investors are watching fall on Friday! The post Penny Stocks Today: Why MEIP and HNST Are Plunging Friday appeared fir...
Why MEI Pharma Stock Is Plummeting After Hours
MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration. D...
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
SAN DIEGO & TOKYO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today provided an update after a recent meeting with the U.S. Food Drug Administra...
MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AA...
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that two abstracts highlighting data from ...
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 31.58% and 139.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, ...
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the expansion of its management team with ...
Will MEI Pharma, Inc. (MEIP) Report Negative Q2 Earnings? What You Should Know
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.